A larger cohort of patients is required to further explore the potential of these findings as well as to investigate whether BRCA1/2 methylation in plasma could serve as a potential prognostic biomarker in pancreatic cancer. The gene discussed is BRCA1; the disease is familial pancreatic carcinoma.